/PRNewswire/ Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer.
Provides extended UK patent coverage relating to lead compound S-pindolol benzoate (ACM-001.1) to 2040. International patent application also filed in March 2021. LONDON, May 4, 2022 /PRNewswire/
- Actimed Therapeutics initiates the company's first clinical study of the pharmacokinetics and pharmacodynamics (PK/PD) for a new salt of S-pindolol (ACM-001.1) - This study is a prelude
/PRNewswire/ Actimed Therapeutics Ltd announces that following regulatory approval from the UK Regulatory Agency, it has commenced a clinical study in.
/PRNewswire/ Actimed Therapeutics Ltd announces that following regulatory approval from the UK Regulatory Agency, it has commenced a clinical study in.